Published: 4 May 2022
Author(s): Jacopo Francesco Imberti, Davide Antonio Mei, Marco Vitolo, Niccolò Bonini, Marco Proietti, Tatjana Potpara, Gregory Y.H. Lip, Giuseppe Boriani
Issue: July 2022
Section: Beyond the Guidelines

Clinical practice in atrial fibrillation (AF) patient management is constantly evolving. Non-vitamin K antagonist oral anticoagulants (NOACs) showed a favorable risk-benefit profile as compared to warfarin [1] and their prescription is encouraged by current AF guidelines [2–6] whenever appropriate.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.